Hypersplenism

Summary

Hypersplenism (MONDO:0006795) is a disease and 10 clinical trials. Top therapeutic interventions include valproic acid, mecrylate, and somatostatin. A subtype of splenic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hypersplenism
Mondo ID	MONDO:0006795
EFO	EFO:1000975
MeSH	D006971
DOID	DOID:6376
ICD-10-CM	D73.1
ICD-11	2093549625
NCIT	C34714
SNOMED CT	58381000
UMLS	C0020532
MedGen	9372
GARD	0024476
MedDRA	10020769
Is cancer (heuristic)	no

Also known as: hypersplenia · hypersplenism · hypersplenism (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of splenic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › splenic disorder › hypersplenism

Related subtypes (7): splenic sequestration, splenic abscess, splenic tuberculosis, splenic infarction, spleen neoplasm, congestive splenomegaly, wandering spleen

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00605657	PHASE1/PHASE2	COMPLETED	Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
NCT06292715	Not specified	RECRUITING	Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism
NCT07462091	Not specified	RECRUITING	Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection
NCT07585773	Not specified	NOT_YET_RECRUITING	Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
NCT07588373	Not specified	NOT_YET_RECRUITING	Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
NCT02261584	Not specified	UNKNOWN	Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism
NCT03269877	Not specified	UNKNOWN	Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension
NCT04692805	Not specified	UNKNOWN	EUS-guided PSE in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension
NCT05055713	Not specified	UNKNOWN	A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
NCT05446116	Not specified	COMPLETED	Transfemoral Versus Transradial Partial Splenic Artery Embolization in Patients With Hypersplenism

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VALPROIC ACID	4	1
MECRYLATE	3	1
SOMATOSTATIN	3	1
SCEPTRIN	0	1